162 related articles for article (PubMed ID: 9449288)
1. Topoisomerase mutations in fluoroquinolone-resistant and methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus.
Kaatz GW; Seo SM
Antimicrob Agents Chemother; 1998 Jan; 42(1):197-8. PubMed ID: 9449288
[TBL] [Abstract][Full Text] [Related]
2. Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.
Takahashi H; Kikuchi T; Shoji S; Fujimura S; Lutfor AB; Tokue Y; Nukiwa T; Watanabe A
J Antimicrob Chemother; 1998 Jan; 41(1):49-57. PubMed ID: 9511037
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.
Takahata M; Yonezawa M; Kurose S; Futakuchi N; Matsubara N; Watanabe Y; Narita H
J Antimicrob Chemother; 1996 Sep; 38(3):543-6. PubMed ID: 8889728
[TBL] [Abstract][Full Text] [Related]
4. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
[TBL] [Abstract][Full Text] [Related]
5. Association of mutations in grlA and gyrA topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant Staphylococcus aureus.
Deplano A; Zekhnini A; Allali N; Couturier M; Struelens MJ
Antimicrob Agents Chemother; 1997 Sep; 41(9):2023-5. PubMed ID: 9303407
[TBL] [Abstract][Full Text] [Related]
6. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
Ng EY; Trucksis M; Hooper DC
Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
[TBL] [Abstract][Full Text] [Related]
7. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
8. [In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].
Yagüe Guirao G; Martínez-Toldos MC; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; Martínez-Andrés JA; Muñoz Bellido JL; García-Rodríguez JA; Segovia Hernández M
Rev Esp Quimioter; 2000 Sep; 13(3):271-5. PubMed ID: 11086276
[TBL] [Abstract][Full Text] [Related]
9. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
[TBL] [Abstract][Full Text] [Related]
10. Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains.
Wang T; Tanaka M; Sato K
Antimicrob Agents Chemother; 1998 Feb; 42(2):236-40. PubMed ID: 9527766
[TBL] [Abstract][Full Text] [Related]
11. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
Schmitz FJ; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Klootwijk M; Verhoef J; Fluit A; Heinz HP; Köhrer K; Jones ME
J Antimicrob Chemother; 1998 Apr; 41(4):481-4. PubMed ID: 9598779
[TBL] [Abstract][Full Text] [Related]
12. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.
Schmitz FJ; Jones ME; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Fluit A; Verhoef J; Hadding U; Heinz HP; Köhrer K
Antimicrob Agents Chemother; 1998 May; 42(5):1249-52. PubMed ID: 9593159
[TBL] [Abstract][Full Text] [Related]
13. Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus.
Sierra JM; Marco F; Ruiz J; Jiménez de Anta MT; Vila J
Clin Microbiol Infect; 2002 Dec; 8(12):781-90. PubMed ID: 12519351
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.
Fitzgibbon JE; John JF; Delucia JL; Dubin DT
Antimicrob Agents Chemother; 1998 Aug; 42(8):2122-4. PubMed ID: 9687420
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.
Dubin DT; Fitzgibbon JE; Nahvi MD; John JF
Antimicrob Agents Chemother; 1999 Jul; 43(7):1631-7. PubMed ID: 10390214
[TBL] [Abstract][Full Text] [Related]
16. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
Fournier B; Hooper DC
Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
[TBL] [Abstract][Full Text] [Related]
17. Rapid method for detection of gyrA and grlA mutations in unrelated strains of Staphylococci susceptible and resistant to levofloxacin.
Messina C; Cafiso V; Campanile F; Santagati M; Stefani S
New Microbiol; 2001 Oct; 24(4):347-53. PubMed ID: 11718372
[TBL] [Abstract][Full Text] [Related]
18. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA.
Muñoz-Bellido JL; Alonzo Manzanares M; Martínez Andrés JA; Guttiérrez Zufiaurre MN; Ortiz G; Segovia Hernández M; García-Rodríguez JA
Antimicrob Agents Chemother; 1999 Feb; 43(2):354-6. PubMed ID: 9925531
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates.
Muñoz Bellido JL; Alonso Manzanares MA; Yagüe Guirao G; Gutiérrez Zufiaurre MN; Toldos MC; Segovia Hernández M; Garcia-Rodríguez JA
Antimicrob Agents Chemother; 1999 Apr; 43(4):966-8. PubMed ID: 10103212
[TBL] [Abstract][Full Text] [Related]
20. Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates.
Schmitz FJ; Fluit AC; Hafner D; Beeck A; Perdikouli M; Boos M; Scheuring S; Verhoef J; Köhrer K; Von Eiff C
Antimicrob Agents Chemother; 2000 Nov; 44(11):3229-31. PubMed ID: 11036061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
